Tempest Therapeutics Files 8-K
Ticker: TPST · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, 8-k
TL;DR
Tempest Therapeutics updated its office address in a routine 8-K filing.
AI Summary
On April 24, 2025, Tempest Therapeutics, Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are located at 2000 Sierra Point Parkway, Suite 400, Brisbane, California, 94005. The report was filed as of April 28, 2025.
Why It Matters
This filing provides an update on the company's principal executive office location, which is standard procedural information for public companies.
Risk Assessment
Risk Level: low — This filing is a routine update of corporate information and does not contain material non-public information that would typically affect stock price.
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Registrant
- 2000 Sierra Point Parkway, Suite 400, Brisbane, California, 94005 (location) — Principal Executive Offices
- April 24, 2025 (date) — Date of earliest event reported
- April 28, 2025 (date) — Date of Report / Filed As Of Date
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report the company's principal executive offices and to serve as a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 24, 2025.
What is the address of Tempest Therapeutics, Inc.'s principal executive offices?
The address of Tempest Therapeutics, Inc.'s principal executive offices is 2000 Sierra Point Parkway, Suite 400, Brisbane, California, 94005.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Commission File Number for Tempest Therapeutics, Inc.?
The Commission File Number for Tempest Therapeutics, Inc. is 001-35890.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 regarding Tempest Therapeutics, Inc. (TPST).